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IN SEARCH OF MOLECULAR APPROACHES TO IMPROVING 
CANCER THERAPY EFFICACY
E. Cherepenko*, G. Telegeev
Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv, Ukraine
The study of genome rearrangement sites using full genome sequences is an important approach to revealing the nature of cancer 
and finding effective ways for cancer treatment. The progress in DNA sequencing could make the procedure of whole genome  reading 
close to routine procedure of lower cost. The personal analysis of rearranged ends (PARE) method used for rearrangement study 
is reviewed. PARE allows identifying of individual cancer biomarkers making personal medicine possible. Also, the progress in 
“liquid biopsy” technology based on detection of circulating tumor cells in the patient’s blood is shortly summarized. Another 
important approach is the discovered phenomenon of synthetic lethality causing cancer cell death due to appropriate combination 
of mutations in different genes or inhibitors of their protein products. Studies of genome rearrangements and synthetic lethality are 
considered promising for the development of effective cancer treatment approaches.
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Obviously, there comes a time in oncology speaking 
in biblical language to “gather stones” and to evaluate 
the significance of molecular diversity detected in tumor 
cells. Such a feeling may emerge due to the organiza-
tion of the first systemic discussion of numerous results 
obtained in individual cancer treatment. Such discussion 
was organized by the Ist International Congress on per-
sonalized treatment of cancer (Controversies in Persona-
lized Oncology Treatment) that took place in Barce-
lona on 7–10 March, 2013 [1]. Prospects of personalized 
medicine are mostly based on advances in the study 
of the individual characteristics of tumor DNA sequences. 
DNA sequences rearrangements especially frequent 
in cancer genome could currently be localized allowing 
the construction of individual patient’s oncomaps. Another 
important approach is the discovered possibility of the so-
called synthetic lethality. This term is related to tumor cell 
killing with the use of individual molecular combinations 
targeting activity of special enzymes or induction of muta-
tions. These novel approaches can be somewhat simpli-
fied using the so-called “liquid biopsy” as the recently 
discovered possibility of manipulating with cancer patient 
DNA and separate circulating tumor cells (CTC) present 
in blood and possibly in other fluids of the organism. Here 
we discuss some of the molecular approaches that could 
improve treatment of cancer patients
The study of the individual characteristics of DNA 
in cancer patients is becoming easier due to new technolo-
gies: comparable genome hybridization (CGH) and DNA 
sequencing called New Generation Sequencing (NGS). 
Possibility of full genome sequencing allows detecting dif-
ferences in genetic texts of cancer patients in comparison 
with the genome of healthy individuals. Such a healthy 
genome for the comparison purposes is called reference 
genome or reference assembly using the DNA sequencing 
data from a number of healthy donors. Useful information 
can currently be obtained by comparison of a) nucleotide 
sequences of healthy and cancer genomes of different 
individuals, b) genomes of normal and malignant cells 
of the same organism, and c) nucleotide sequences of tu-
mors of different histological types. Thus, the develo ped 
technologies opened a powerful way for the genetic map-
ping [2]. Analysis of oncomaps allowed separate the genes 
carrying cancer-related mutations into two groups: driver 
and passenger as to whether they do or do not influence 
the malignant cell reproduction rate and hence the growth 
of the tumor [3]. Interesting, could the genomic rearrange-
ments present in cancer patient be divided alike?
The opened possibilities to study sequence 
alterations in full cancer genomes draw attention 
to genome rearrangements. Until recently the main 
efforts in tumor DNA studies were focused mainly on two 
things. The first is single nucleotide polymorphism (SNP) 
presented by different point mutations and the so-
called indel mutations (associated with insert or loss 
of nucleotides-deletion). And the second one is mainly 
due to the processes of nucleotide loss or conversely 
amplification that change the number of gene copies 
in genome. Previously it was called CNV — copy number 
variation, and later a new term aCGH (array comparative 
genome hybridization) appeared. Numerous sequence 
alterations found in cancer patient DNA are currently 
covered by specially developed databases. As an example 
954,247 mutations in 2680 exomes of 14 cancer types 
could be studied [4]. These databases include The Cancer 
Genome Atlas — TCGA data; COSMIC — Cancer Gene 
Census; CRAVAT — Cancer-Related Analysis of VArients 
Toolkit, and others that are comprehensively summarized 
in the work [4 and references therein].
In recent years the genetic rearrangements in cancer 
cell genomes and their functional role are of particular 
interest in connection with the previously established 
fact of aneuploidy in tumor cells [5–9]. Aneuploidy 
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is  characteristic to cancer cell as well as the inherent insta-
bility of cell cancer genome leading to numerous genomic 
rearrangements and chromosomal chaos [5–7]. Many 
authors have addressed a question how aneuploidy and 
genome instability may be associated [3, 10]. In the study 
[10] there have been compared the results of cancer 
cells study at the level of karyotypic changes and that 
of individual genes mutability, without going into details 
on the genes being drivers or passengers. The most 
informative name of a novel approach is the classic one 
“Whole genome vs selected gene panel approach” [11].
The possibility of full genome sequencing and detec-
tion of genomic rearrangement sites allows experimental 
studies of deregulation of cancer cell work as a functional 
single system. Study of genome rearrangements may 
deepen insights on cell organization.
Study of genomic rearrangements using 
PARE method. Development of high-tech methods 
of  sequencing, extremely optimized and less expensive for 
reading full genome texts, even very large and complex, 
provided the possibility of detecting various reorganiza-
tions of the genome, in particular, changes in nucleotide 
sequences resulted from formation of different gap(s) 
and illegitimate reunion of different genome fragments.
An efficacious method to study the genomic rear-
rangements in cancer cells is a method called PARE 
(personalized analysis of rearranged ends) [12]. We briefly 
describe here this technology.
It is clear that full genome sequences could be com-
pared in the manner base by base. However, because 
the patient genome size is about 3 billion nucleotides, 
the work would be too expensive and unjustified for 
clinical use. At the same time, simultaneous examination 
of only short sequences at both ends of the same DNA 
molecule of fragmented genome is the way to simplifica-
tion. The known distance apart both DNA molecule ends 
allows getting rid of the nucleotide content between 
the two ends. The identification of these end sequences 
occurs as if in paired form, in the form of these ends ma-
ting (mate-paired ends). Then mapping of these ends 
to fully sequenced genome significantly simplifies and 
reduces the cost of finding rearranged sites in genome. 
Using this approach, it is possible to consider the influence 
of repeated and amplified sequence first of all when com-
paring molecules belonging respectively to the genomes 
of normal and malignant cells. So, this technique account-
ing nucleotide changes at sites of repeated and ampli-
fied sequences, allows identifying such a combination 
of nucleotide text in the molecules of cancer genome that 
is not detected in the molecules of a fragmented genome 
of normal cells. Detection of molecules that carry such 
a nucleotide combination indicates that these molecules 
come from genome sites where rearrangement via both 
intra- and interchromosomal translocations occurs.
To characterize the logic of an approach to study 
genetic rearrangements using PARE we briefly describe 
one example. Genomic DNA is fragmented using me-
chanical efforts and ends of molecules obtained are 
repaired  using biotin label. Then such molecules are 
circulated and cleared of noncircular DNA using nuclease 
digestion. Circular molecules obtained are fragmented 
again, and catching biotin label using magnetic beads 
with the streptavidin allows obtaining of fragments of uni-
form size that contain only the end sequence of the same 
original mole cule. The ends of the DNA molecules obtained 
in such a manner are also repaired and are surrounded 
by the sequences of special adaptors and primers that allow 
sequencing 25 nucleotide end tags. Performing emulsion 
PCR allows landing on a magnetic bead of only one DNA 
molecule. In this manner the library of end sequences can 
be obtained and fixed on a hard surface for sequencing 
in the form of amplicons, or DNA colonies, or using new 
terminology DNA clusters. In the resulting mate-paired end 
library, different molecules of the genome are sequenced. 
Modern equipment and methods allow simultaneous se-
quencing up to 500 000 of such mo lecules (massive parallel 
sequencing) per a sequencer run. Currently, nucleotide 
sequencing exploits two principles: sequencing by using 
template synthesis, classical Sanger sequencing and se-
quencing by oligonucleotide ligation [13]. There has been 
great progress in the development of equipment, analyzing 
signals produced by both types of sequencing.
The success of the molecular approach to finding 
individual tumor markers based on the PARE method 
and its practical use in medicine has been demonstrated 
in the work by V. Velculescu et al. [12]. In the referred 
work the pair ends study approach originally designed 
by Applied Biosystems SOLiD system was used. Using 
the reference genome, studying the genome of solid can-
cers compared respectively to the patient healthy tissue 
genome, the authors analyzed the short end sequence for 
each DNA sample of roughly 40 million reads. The posi-
tions of these reads at the reference genome were defined 
exactly. The total nucleotide number of analyzed end 
sequences was increased by the value of nucleotides be-
tween the ends of the studied molecules. Considering the 
study of the number of mate-paired end tags molecules 
represented in the library, the performed sequencing 
resulted in 18-fold physical coverage of the human ge-
nome, i.e. with very high probability this analysis covered 
the whole genome completely.
The detection of individual cancer biomarkers. 
An important result of the work [12] was the demon-
stration of the discovery of an individual oncomarker 
in a colon cancer patient and the detection in the blood 
plasma (possibly in other body fluids) of tumor mutant 
DNA with modifications that distinguish it from normal cell 
DNA. The possibility of manipulations with the cancer cell 
DNA circulating in the patient’s blood was convincingly 
demonstrated.
It turned out that the mutant DNA, identified only 
in the tumor cells of a studied patient is characterized 
by a translocation of sequences between 4 and 8 chromo-
somes — 4: 8 translocation. Two methods were used to find 
it. According to one of them mo lecules that contained 
sequences belonging to diffe rent chromosomes have 
been selected from the end tag libraries and the genome 
text was studied at the distance between end tags equal 
to 1 kb. If an unusual combination of nucleotides has been 
detected in this group of molecules at least 5 times, such 
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carriers have been chosen to further research using PCR 
primer specific for translocation breakpoints. In the case 
of healthy DNA corresponding PCR products were not 
found, by they were identified in case of the cancer DNA.
The second method for search of rearranged sequenc-
es in cancer cells using mate-paired end  sequencing 
approach allows distinguishing between real transloca-
tion breakpoints from those that appear due to genome 
repetitive and amplified sequences. In this case, the work 
with tags was carried out on the 3 kb genome sequences. 
Determination of tags density occurrence on a single 
molecule and on the total number of mo lecules of this 
group allows determining which sites found are related 
to genome amplification processes and which are real 
rearranged sequences of a cancer cell. Studying in this 
manner DNA from 5 different cancer patients, the translo-
cation 4: 8 was identified only in one of them. The particular 
value of this result is that no comparison of the cancer 
and normal cell genomes is needed. This halves the cost 
of the analysis making the price acceptable to the broader 
range of patients.
Identification of 4: 8 marker in a cancer cell genome has 
enabled to determine the sensitivity of the measurement 
in the presence of various DNA impurities originated from 
healthy tissues. It turned out that using a primer annealing 
to 4: 8 rearrangement breakpoint allows revealing a cancer 
cell genome equivalent in the presence of 390 000 normal 
genome equivalents. So, in the plasma of a patient blood the 
presence of tumor DNA can be detected at the concentra-
tion less than 0.001% of the content of all DNA in the sample. 
The capability to detect the circulation of the mutant DNA 
in the body simplifies, accelerates and diversifies the ap-
proaches to various cancer research. It is clear that this 
identified rearrangement of sequences could be exploited 
not only as a personal biomarker but also allows studying 
biochemical and physiological changes induced in the cell 
due to such rearrangement.
Moreover, an individual 4: 8 chromosome translocation 
biomarker simplifies the study of the efficacy of chemo-
therapy because it improves monitoring of the marker 
in blood samples. It opens the prospect for an individual 
cancer therapy. However, this approach may face certain 
limitations due to malignant cells heterogeneity observed 
in the same tumor that is associated with the cancer ge-
nome instability. The tumor cells at any given moment are 
presented in the form of different clones, as well as their 
different subclones. In the work [14] it has been shown that 
the study of genomic polymorphism of fully sequenced 
tumor DNA exons allows comparing the level of clonal 
heterogeneity and their proliferation rates.
We note here also that the heterogeneity of tumor cells 
stimulates developing the technology that allows the se-
lection of a single cell; an accurate characterization of DNA 
from such a cell improves characterization of the studied 
clone and its different subclones. Obtaining of such 
cells is possible using with the aid of a laser technique, 
so-called Laser Capture Microdissection — LCM [15]. 
The DNA obtained in this way contains sequences of a full 
genome. By means of amplification and fragmentation 
it could be used for preparing a library of molecules ready 
for the mate-paired ends sequencing and identification 
of rearrangement sites.
Circulating tumor cells. The study of CTC in peri-
pheral blood of patients with solid tumors of epithelial origin 
is also currently an area of intense studies [16]. Moreover, 
it was found that tumor progression is accompanied 
by appearance of disseminating tumor cells (DTC) homing 
mainly in the bone marrow where they can stay dormant 
for years due to yet undisclosed reasons [17–19].
Various sensitive methods of isolation of CTC from 
blood including the “liquid biopsy” are developed. 
Methods are based on different principles: the use of dif-
ferences in physical properties (cell density, their size), 
differences in gene expression profile (the cells express 
the marker proteins like adhesion molecule of epithelial 
cells — EpCAM and proteins of cytoske leton filaments — 
cytokeratin). The status of these markers can be evaluated 
by immunostaining, proper results of RT-PCR reactions 
and special EPISPOT analysis [20].
Synthetic lethality. The distinctive feature of cancer 
cell is its genome instability and emerging repair defects 
that make highly probable the mutagenesis processes. 
High levels of mutagenesis in tumor cell can decrease 
the efficacy of targeted therapy. Therefore, the success 
of chemotherapy depends on the ability to inhibit muta-
genesis processes.
The studies of different gene mutation effects showed 
that when mutations in some genes are induced in cells 
separately there are no large biological effects, except 
minor phenotypic changes. However, the simultaneous 
mutations in few different genes may result in cancer cell 
death that is called synthetic lethality.
A phenomenon called metabolic bypass is related 
to cell survival in the conditions of the loss of a gene  leading 
to total absence of an enzyme activity [21]. It means 
an existence of some biochemical compensating mecha-
nisms buffering the possible effects of emerging genetic 
changes. A special review [22] is dedicated to the prin-
ciples for the work of such buffer mechanisms. Moreover, 
in a chapter of the book [21] we have shown that an ef-
ficacious approach to the study of the cellular potential 
buffer mechanisms might be the study of artifacts revealed 
during gene cloning using genetic complementation 
methods. Interestingly, these artifacts may belong quite 
to different metabolic pathways.
So, if the synthetic lethality can be an efficient method 
for cancer cells elimination from the body, the search 
of such possible combinations is perspective. Here 
we present some results of studies in the field of synthetic 
lethality.
Simultaneously the two groups of researchers have 
found that treatment of breast cancer cell cultures 
with a target inhibitor of poly-ADP-ribose polymerase 
(PARP) resulted in massive cell death [23]. PARP is in-
volved in the reparation processes, in particular, in repair 
of single strand breaks — SSB using base excision repair 
BER. When PARP “senses” SSB it undergoes structural 
change, interacts with coenzyme nicotinamide adenin 
dinucleotide (NAD+) and cleaves it producing nicotina mide 
and ADP-ribose that PARP polymerises to highly  negative 
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chains — PAR. As a result of this reaction, a reparative 
active protein complex containing PAR-PARP is formed 
at the site of DNA reparation. Interestigly, when PARP 
binds its inhibitor, the enzyme interacts with DNA, but 
can’t dissociate from it what makes DNA replication im-
possible [24]. It was studied why breast cancer cells unlike 
healthy cells die when they were treated using the inhibitor 
that competes with NAD+ for binding with the PARP and 
thus disabling the enzyme of capacity to repair DNA 
strands breaks. It turned out that genome reparation is car-
ried out through various mechanisms, and some of them 
are overlapping. It is known that in breast cancer patients 
there is malfunction of BRCA 1 and BRCA2 genes. The first 
gene is involved in repair of double strand breaks — DSB 
and the second one is responsible for homologous re-
combination. However, if these genes do not function 
in breast cancer cells because of mutations induced then 
PARP begins to fulfill their work. Clearly, the PARP inhibitor 
deprives the cell of the last chance to maintain its genome 
intact and emerged in this case synthetic lethality dooms 
cell to death. Currently the role of synthetic lethality po-
tential in conjunction with that of the reparation processes 
for the successful treatment of breast cancer is intensely 
studied [25–27].
The repair processes and synthetic lethality in the case 
of solid tumors is thought to be influenced by tumor mi-
croenvironment. Using model cell culture experiments 
it has been shown that in condition of hypoxia the genes 
coding for proteins involved in homologous recombination 
are not expressed and no DSB reparation occurs. If PARP 
inhibitor is used, the massive cell death is observed [28].
So, the original technology of possible reading 
the large arrays of DNA sequences known as New Gene-
ration Sequencing allows working with the full genome 
sequences reliably finding the places of genomic rear-
rangements. Study of genome reorganizations raises 
many questions for fundamental research. Currently, new 
opportunities, namely, the study of circulating tumor DNA 
and CTC in the manner of “liquid biopsy” have appeared. 
High levels of mutagenesis observed in cancer cell due 
to many intrinsic factors (for example induction of APOBEC 
mutagenase, imbalance in synthesis of DNA precursors) 
speaking philosophically represent both evil and good. 
The first is frequent loss of cancer cell sensitivity to target 
drugs. The second is the possibility of creating lethal com-
bination of mutations leading to possible synthetic lethality 
of the cell. The important task is learning how to do this 
probability useful and effective for clinical purposes.
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